Clinical study of aumolertinib versus osimertinib in the treatment of EGFR-mutated advanced non-small cell lung cancer.

ABSTRACT:

Background

To compare the efficacy and safety of aumolertinib and osimertinib in the treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.

Methods

A retrospective analysis was performed for patients with EGFR-mutant NSCLC. The primary outcome was median progression-free survival (mPFS). Kaplan-Meier curves and the log-rank test were used to evaluate PFS and overall survival (OS), Cox regression was used for prognostic factors assessment.

Results

A total of 202 patients were included, comprising 106 aumolertinib users and 96 osimertinib users. In the first-line treatment, no significant difference was observed in mPFS between aumolertinib and osimertinib group (19.0 months; hazard ratio [HR], 1.15; 95% confiden

SUBMITTER: Yang SX 

PROVIDER: S-EPMC12500483 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature